172 related articles for article (PubMed ID: 2123602)
1. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.
Bleich SD; Nichols TC; Schumacher RR; Cooke DH; Tate DA; Teichman SL
Am J Cardiol; 1990 Dec; 66(20):1412-7. PubMed ID: 2123602
[TBL] [Abstract][Full Text] [Related]
2. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
[TBL] [Abstract][Full Text] [Related]
3. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
GUSTO Angiographic Investigators
N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
[TBL] [Abstract][Full Text] [Related]
4. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
Hsia J; Kleiman N; Aguirre F; Chaitman BR; Roberts R; Ross AM
J Am Coll Cardiol; 1992 Jul; 20(1):31-5. PubMed ID: 1607535
[TBL] [Abstract][Full Text] [Related]
5. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
[TBL] [Abstract][Full Text] [Related]
6. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
[TBL] [Abstract][Full Text] [Related]
7. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
[TBL] [Abstract][Full Text] [Related]
8. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
Thompson PL; Aylward PE; Federman J; Giles RW; Harris PJ; Hodge RL; Nelson GI; Thomson A; Tonkin AM; Walsh WF
Circulation; 1991 May; 83(5):1534-42. PubMed ID: 1902404
[TBL] [Abstract][Full Text] [Related]
10. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Johns JA; Gold HK; Leinbach RC; Yasuda T; Gimple LW; Werner W; Finkelstein D; Newell J; Ziskind AA; Collen D
Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953
[TBL] [Abstract][Full Text] [Related]
11. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study.
Verheugt FW; Liem A; Zijlstra F; Marsh RC; Veen G; Bronzwaer JG
J Am Coll Cardiol; 1998 Feb; 31(2):289-93. PubMed ID: 9462569
[TBL] [Abstract][Full Text] [Related]
12. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
Anderson JL; Becker LC; Sorensen SG; Karagounis LA; Browne KF; Shah PK; Morris DC; Fintel DJ; Mueller HS; Ross AM
J Am Coll Cardiol; 1992 Oct; 20(4):753-66. PubMed ID: 1527286
[TBL] [Abstract][Full Text] [Related]
13. Patency trials with reteplase (r-PA): what do they tell us?
Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
[TBL] [Abstract][Full Text] [Related]
14. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
Hsia J; Hamilton WP; Kleiman N; Roberts R; Chaitman BR; Ross AM
N Engl J Med; 1990 Nov; 323(21):1433-7. PubMed ID: 2122251
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
[TBL] [Abstract][Full Text] [Related]
16. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.
Topol EJ; Ellis SG; Califf RM; George BS; Stump DC; Bates ER; Nabel EG; Walton JA; Candela RJ; Lee KL
J Am Coll Cardiol; 1989 Oct; 14(4):877-84. PubMed ID: 2477426
[TBL] [Abstract][Full Text] [Related]
17. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
[TBL] [Abstract][Full Text] [Related]
18. Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group.
Haq A; Morgan CD; Wilson RF; Daly PA; Baigrie RS; White CW; Roberts R; Gent M; Armstrong PW
Am J Cardiol; 1993 Aug; 72(5):379-83. PubMed ID: 8352178
[TBL] [Abstract][Full Text] [Related]
19. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
[TBL] [Abstract][Full Text] [Related]
20. Ridogrel as an adjunct to thrombolysis in acute myocardial infarction.
van der Wieken LR; Simoons ML; Laarman GJ; Van den Brand M; Nijssen KM; Dellborg M; Hermens W; Vrolik W
Int J Cardiol; 1995 Nov; 52(2):125-34. PubMed ID: 8749872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]